Liquidia Corporation (LQDA)

Market Cap	1.31B
Revenue (ttm)	14.14M
Net Income (ttm)	-138.68M
Shares Out	85.45M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,264,354
Open	15.10
Previous Close	15.53
Day's Range	15.00 - 15.81
52-Week Range	8.26 - 16.81
Beta	0.24
Analysts	Strong Buy
Price Target	28.67 (+86.78%)
Earnings Date	May 8, 2025

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2024, Liquidia's revenue was $14.00 million, a decrease of -19.97% compared to the previous year's $17.49 million. Losses were -$130.39 million, 66.1% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price forecast is $28.67, which is an increase of 86.78% from the latest price.

Price Target

$28.67

(86.78% upside)

Analyst Consensus: Strong Buy